Answers are grounded in this paper and cite their sources.
Phase 1B/2 trial shows neoadjuvant therapy impacts clinical outcomes in NSCLC, suggesting future directions in treatment.
Our results support the feasibility of neoadjuvant systemic therapy in resectable NSCLC and explore the novel combination of nivolumab with denosumab. CD8 T-cell infiltration correlates with pathological response, warranting ongoing translational research to better understand patient selection for such novel combinations.
No takes yet. Share an insight, caveat, or question.
Ahern et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: